Treatment of myelitis in Behçet's disease with rituximab

Maria J osè Messina, Mariaemma Rodegher, Roberta Scotti, Vittorio Martinelli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Behçet's disease (BD) is a chronic inflammatory disorder that involves the parenchymal central nervous system (neuro-BD, NBD) approximately in 5-49% of patients, causing lesions rarely located in the spinal cord (SC). We report the first case of NBD-myelitis treated with intravenous rituximab. A 41-year-old man affected by BD presented with mild paraparesis with a miliary involvement and a 'net-like' gadolinium enhancement (Gde) of the SC. After a therapeutic attempt with pulsed cyclophosphamide and intravenous methylprednisolone, the clinical and neuroradiological course worsened. A progressive improvement was observed after rituximab administration associated with low doses of oral prednisone. No disease activity was detected and the patient reported no adverse event. After six rituximab cycles, cervical MRI was normal while thoracic MRI showed a slight T2-weighted hyperintensity of D4-D10 spinal tract without Gde. A combined use of rituximab and oral steroids resulted in a long-term suppression of NBD activity without any safety concern.

Original languageEnglish
JournalBMJ Case Reports
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Myelitis
Gadolinium
Spinal Cord
Paraparesis
Methylprednisolone
Therapeutics
Prednisone
Cyclophosphamide
Thorax
Central Nervous System
Steroids
Safety
Rituximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of myelitis in Behçet's disease with rituximab. / Messina, Maria J osè; Rodegher, Mariaemma; Scotti, Roberta; Martinelli, Vittorio.

In: BMJ Case Reports, Vol. 2014, 2014.

Research output: Contribution to journalArticle

@article{146967a9d5cb4603a6cb4cf119a197b4,
title = "Treatment of myelitis in Beh{\cc}et's disease with rituximab",
abstract = "Beh{\cc}et's disease (BD) is a chronic inflammatory disorder that involves the parenchymal central nervous system (neuro-BD, NBD) approximately in 5-49{\%} of patients, causing lesions rarely located in the spinal cord (SC). We report the first case of NBD-myelitis treated with intravenous rituximab. A 41-year-old man affected by BD presented with mild paraparesis with a miliary involvement and a 'net-like' gadolinium enhancement (Gde) of the SC. After a therapeutic attempt with pulsed cyclophosphamide and intravenous methylprednisolone, the clinical and neuroradiological course worsened. A progressive improvement was observed after rituximab administration associated with low doses of oral prednisone. No disease activity was detected and the patient reported no adverse event. After six rituximab cycles, cervical MRI was normal while thoracic MRI showed a slight T2-weighted hyperintensity of D4-D10 spinal tract without Gde. A combined use of rituximab and oral steroids resulted in a long-term suppression of NBD activity without any safety concern.",
author = "Messina, {Maria J os{\`e}} and Mariaemma Rodegher and Roberta Scotti and Vittorio Martinelli",
year = "2014",
doi = "10.1136/bcr-2014-204366",
language = "English",
volume = "2014",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BRITISH INST RADIOLOGY",

}

TY - JOUR

T1 - Treatment of myelitis in Behçet's disease with rituximab

AU - Messina, Maria J osè

AU - Rodegher, Mariaemma

AU - Scotti, Roberta

AU - Martinelli, Vittorio

PY - 2014

Y1 - 2014

N2 - Behçet's disease (BD) is a chronic inflammatory disorder that involves the parenchymal central nervous system (neuro-BD, NBD) approximately in 5-49% of patients, causing lesions rarely located in the spinal cord (SC). We report the first case of NBD-myelitis treated with intravenous rituximab. A 41-year-old man affected by BD presented with mild paraparesis with a miliary involvement and a 'net-like' gadolinium enhancement (Gde) of the SC. After a therapeutic attempt with pulsed cyclophosphamide and intravenous methylprednisolone, the clinical and neuroradiological course worsened. A progressive improvement was observed after rituximab administration associated with low doses of oral prednisone. No disease activity was detected and the patient reported no adverse event. After six rituximab cycles, cervical MRI was normal while thoracic MRI showed a slight T2-weighted hyperintensity of D4-D10 spinal tract without Gde. A combined use of rituximab and oral steroids resulted in a long-term suppression of NBD activity without any safety concern.

AB - Behçet's disease (BD) is a chronic inflammatory disorder that involves the parenchymal central nervous system (neuro-BD, NBD) approximately in 5-49% of patients, causing lesions rarely located in the spinal cord (SC). We report the first case of NBD-myelitis treated with intravenous rituximab. A 41-year-old man affected by BD presented with mild paraparesis with a miliary involvement and a 'net-like' gadolinium enhancement (Gde) of the SC. After a therapeutic attempt with pulsed cyclophosphamide and intravenous methylprednisolone, the clinical and neuroradiological course worsened. A progressive improvement was observed after rituximab administration associated with low doses of oral prednisone. No disease activity was detected and the patient reported no adverse event. After six rituximab cycles, cervical MRI was normal while thoracic MRI showed a slight T2-weighted hyperintensity of D4-D10 spinal tract without Gde. A combined use of rituximab and oral steroids resulted in a long-term suppression of NBD activity without any safety concern.

UR - http://www.scopus.com/inward/record.url?scp=84990013364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990013364&partnerID=8YFLogxK

U2 - 10.1136/bcr-2014-204366

DO - 10.1136/bcr-2014-204366

M3 - Article

VL - 2014

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

ER -